Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.

Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, Tedeschi M

Annals of oncology : official journal of the European Society for Medical Oncology1 Jun 1997Cited by 104 (Europe PMC)

PMID9261526DOI10.1023/a:1008211226339PepBankPUB-09261526

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with ovarian cancer, glutathione increased receipt of six cisplatin courses at any dose versus control.
In plain wordsIn patients with ovarian cancer, more patients received six chemotherapy courses with glutathione than control.
Peptide
Glutathione
Outcome
IncreaseReceipt of six cisplatin courses
Study
n = 151
Comparator
Cisplatin control without glutathione
Outcome group
Treatment adherence and retention · Cancer
Studied dose
Dose not stated
Measurements
Patients receiving six cisplatin courses at any dose
58%
GSH group
Patients receiving six cisplatin courses at any dose
39%
control group
P value
0.04
Receipt of six cisplatin courses at any dose: GSH group versus control group
Source sentences
Summary
When considering the proportion of patients receiving six courses of CDDP at any dose, GSH produced a significant advantage over control--58% versus 39%, (P = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152601
02HumanRandomized controlled trialSafety outcome
In patients with ovarian cancer, glutathione improved the hair loss quality of life score versus control.
In plain wordsIn patients with ovarian cancer, glutathione improved the hair loss score compared with control.
Peptide
Glutathione
Outcome
DecreaseHair loss quality of life score
Study
n = 151
Comparator
Cisplatin control without glutathione
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152606
03HumanRandomized controlled trialSafety outcome
In patients with ovarian cancer, glutathione improved the shortness of breath quality of life score versus control.
In plain wordsIn patients with ovarian cancer, glutathione improved the breathlessness score compared with control.
Peptide
Glutathione
Outcome
DecreaseShortness of breath quality of life score
Study
n = 151
Comparator
Cisplatin control without glutathione
Outcome group
Adverse events · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152607
04HumanRandomized controlled trialEfficacy outcome
In patients with ovarian cancer, glutathione improved the difficulty concentrating quality of life score versus control.
In plain wordsIn patients with ovarian cancer, glutathione improved the concentration difficulty score compared with control.
Peptide
Glutathione
Outcome
DecreaseDifficulty concentrating quality of life score
Study
n = 151
Comparator
Cisplatin control without glutathione
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152608
05HumanRandomized controlled trialEfficacy outcome
In patients with ovarian cancer, glutathione improved ability to undertake housekeeping versus control.
In plain wordsIn patients with ovarian cancer, glutathione improved ability to do housekeeping compared with control.
Peptide
Glutathione
Outcome
IncreaseAbility to undertake housekeeping
Study
n = 151
Comparator
Cisplatin control without glutathione
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated
Source sentences
Summary
As an indication of overall activity, these patients were statistically significantly more able to undertake housekeeping and shopping.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152609
06HumanRandomized controlled trialEfficacy outcome
In patients with ovarian cancer, glutathione improved ability to undertake shopping versus control.
In plain wordsIn patients with ovarian cancer, glutathione improved ability to shop compared with control.
Peptide
Glutathione
Outcome
IncreaseAbility to undertake shopping
Study
n = 151
Comparator
Cisplatin control without glutathione
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated
Source sentences
Summary
As an indication of overall activity, these patients were statistically significantly more able to undertake housekeeping and shopping.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152610
07HumanRandomized controlled trialEfficacy outcome
In patients with ovarian cancer, response was 73% with glutathione versus 62% with control, without a significant difference.
In plain wordsIn patients with ovarian cancer, treatment response did not differ significantly between glutathione and control.
Peptide
Glutathione
Outcome
No significant changeClinical treatment response
Study
n = 151
Comparator
Cisplatin control without glutathione
Outcome group
Cancer treatment response · Cancer
Studied dose
Dose not stated
Measurements
Clinical treatment response rate
73%
GSH group
Clinical treatment response rate
62%
Control group
P value for clinical treatment response
0.25
GSH group versus control
Source sentences
Summary
Clinically assessed response to treatment demonstrated a trend towards a better outcome in the GSH group (73% versus 62%) but this was not statistically significant (P = 0.25).
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152611
08HumanRandomized controlled trialSafety outcome
Among patients receiving six cisplatin courses, creatinine clearance reduction differed significantly with glutathione versus control, reported as 74% versus 62%.
In plain wordsAmong patients receiving six chemotherapy courses, the reported kidney clearance reduction differed between glutathione and control.
Peptide
Glutathione
Outcome
Direction not reportedCreatinine clearance reduction
Study
n: not reported in source
Comparator
Cisplatin control without glutathione
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
Creatinine clearance reduction as reported
74%
GSH treated patients receiving six cisplatin courses
Creatinine clearance reduction as reported
62%
control patients receiving six cisplatin courses
P value
0.006
Creatinine clearance reduction among patients receiving six cisplatin courses: GSH treated patients versus control
Source sentences
Summary
For these patients there was a significant difference between the reduction in creatinine clearance for GSH treated patients compared with control--74% versus 62% (P = 0.006).
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152602
09HumanRandomized controlled trialEfficacy outcome
In patients with ovarian cancer, glutathione improved the depression quality of life score versus control.
In plain wordsIn patients with ovarian cancer, glutathione improved the depression score compared with control.
Peptide
Glutathione
Outcome
DecreaseDepression quality of life score
Study
n: not reported in source
Comparator
Cisplatin control without glutathione
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152603
10HumanRandomized controlled trialSafety outcome
In patients with ovarian cancer, glutathione improved the emesis quality of life score versus control.
In plain wordsIn patients with ovarian cancer, glutathione improved the vomiting score compared with control.
Peptide
Glutathione
Outcome
DecreaseEmesis quality of life score
Study
n: not reported in source
Comparator
Cisplatin control without glutathione
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152604
11HumanRandomized controlled trialSafety outcome
In patients with ovarian cancer, glutathione improved the peripheral neurotoxicity quality of life score versus control.
In plain wordsIn patients with ovarian cancer, glutathione improved the peripheral nerve toxicity score compared with control.
Peptide
Glutathione
Outcome
DecreasePeripheral neurotoxicity quality of life score
Study
n: not reported in source
Comparator
Cisplatin control without glutathione
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH).
Summary · context
The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.
Report a problemFND-0926152605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.